Palsonify, a once-daily oral SST2 agonist, offers a noninvasive alternative to monthly depot injections, long considered the standard medical therapy for acromegaly.
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
The compounds have exploded in popularity, but big questions about safety and effectiveness are still unresolved.
Objectives To investigate the potential long-term impacts of adult growth hormone deficiency (GHD). Design Observational, retrospective matched cohort. Setting UK Clinical Practice Research Datalink ...
Scaling a company across borders is difficult. Scaling one whose “product” is human transformation—delivered live, in real time, through conversation—would seem nearly impossible. Yet Landmark, one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results